Literature DB >> 32754780

Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population.

Haiden A Huskamp1, Sharon Reif2, Shelly F Greenfield3,4, Sharon-Lise T Normand5,6, Alisa B Busch5,3,4.   

Abstract

OBJECTIVE: Examine patterns of alcohol use disorder (AUD) medication use and identify factors associated with prescription fill among commercially insured individuals with an index AUD visit.
DESIGN: Using 2008-2018 claims data from a large national insurer, estimate days to first AUD medication using cause-specific hazards approach to account for competing risk of benefits loss. PARTICIPANTS: Aged 17-64 with ≥ 1 AUD visit. MAIN MEASURE: Days to AUD medication fill. KEY
RESULTS: A total of 13.3% of the 151,128 with an index visit filled an AUD prescription after that visit, while 69.8% lost benefits before filling and 17.0% remained enrolled but did not fill (median days observed = 305). Almost half (46.3%) of those who filled a prescription received substance use disorder (SUD) inpatient care within 7 days before the fill, and 63.4% received SUD outpatient care. Likelihood of medication use was higher for those aged 26-35, 36-45, and 46-55 years relative to 56-64 years (e.g., 26-35: hazard ratio = 1.29 [95% confidence interval 1.23-1.36]); those diagnosed with moderate/severe AUD (2.05 [1.98-2.12]), co-occurring opioid use disorder (OUD) (1.33 [1.26-1.39]), or severe mental illness (1.31 [1.27-1.35]); those with a chronic alcohol-related diagnosis (1.08 [1.04-1.12]); and those whose index visit was in an inpatient/emergency department (1.27 [1.23-1.31]) or intermediate care setting (1.13 [1.07-1.20]) relative to outpatient. Likelihood of use was higher in later years relative to 2008 (e.g., 2018:2.02 [1.89-2.15]) and higher for those who received the majority of AUD care in a practice with a psychiatrist/addiction medicine specialist (1.13 [1.10-1.16]). Likelihood of use was lower for those diagnosed with a SUD other than AUD or OUD (0.88 [0.85-0.92]), those with an acute alcohol-related condition (0.79 [0.75-0.84]), and males (0.71 [0.69-0.73]).
CONCLUSIONS: While AUD medication use increased and was more common among individuals with greater severity, few patients who could benefit from medications are using them. More efforts are needed to identify and treat individuals in non-acute care settings earlier in their course of AUD.

Entities:  

Keywords:  alcohol use disorder; medication; substance use disorder

Mesh:

Year:  2020        PMID: 32754780      PMCID: PMC7661665          DOI: 10.1007/s11606-020-06073-w

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  23 in total

1.  Availability of addiction medications in private health plans.

Authors:  Constance M Horgan; Sharon Reif; Dominic Hodgkin; Deborah W Garnick; Elizabeth L Merrick
Journal:  J Subst Abuse Treat       Date:  2007-05-17

2.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

Review 3.  Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Elizabeth A O'Connor; Leslie A Perdue; Caitlyn A Senger; Megan Rushkin; Carrie D Patnode; Sarah I Bean; Daniel E Jonas
Journal:  JAMA       Date:  2018-11-13       Impact factor: 56.272

4.  Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017.

Authors:  Haiden A Huskamp; Lauren E Riedel; Colleen L Barry; Alisa B Busch
Journal:  Med Care       Date:  2018-06       Impact factor: 2.983

5.  Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.

Authors:  Tami L Mark; Cheryl A Kassed; Rita Vandivort-Warren; Katharine R Levit; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2008-09-25       Impact factor: 4.492

6.  Counselor attitudes toward pharmacotherapies for alcohol dependence.

Authors:  Amanda J Abraham; Lori J Ducharme; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

Review 7.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

8.  Physicians' opinions about medications to treat alcoholism.

Authors:  Tami L Mark; Henry R Kranzler; Xue Song; Peace Bransberger; Virginia H Poole; Scott Crosse
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

9.  Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.

Authors:  Susanne Rösner; Stefan Leucht; Philippe Lehert; Michael Soyka
Journal:  J Psychopharmacol       Date:  2008-01       Impact factor: 4.153

Review 10.  Effectiveness of brief alcohol interventions in primary care populations.

Authors:  Eileen Fs Kaner; Fiona R Beyer; Colin Muirhead; Fiona Campbell; Elizabeth D Pienaar; Nicolas Bertholet; Jean B Daeppen; John B Saunders; Bernard Burnand
Journal:  Cochrane Database Syst Rev       Date:  2018-02-24
View more
  3 in total

1.  Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.

Authors:  Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre
Journal:  Drug Alcohol Depend       Date:  2021-09-28       Impact factor: 4.492

2.  Response to Letter to Editor from Drs. Barrett and Apodaca.

Authors:  Shelly F Greenfield; Dawn E Sugarman
Journal:  J Gen Intern Med       Date:  2021-05-04       Impact factor: 6.473

3.  U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016.

Authors:  Joshua D Wallach; Taeho Greg Rhee; E Jennifer Edelman; Nilay D Shah; Stephanie S O'Malley; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2021-03-05       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.